MEJORA DE LA PATENTE PEPTIDOS DERIVADOS DE UNA PROTEINA LACTEA CON ACTIVIDAD INHIBIDORA DE LA ENZIMA CONVERSORA DE ANGIOTENSINA I

The invention consists in the use of bioactive products derived from dairy proteins - lactoferrin - and the hydrolyzate of lactoferrin that contains said products. This involves a peptide with fifteen amino acid residues (called LfcinB 17-31), and another that is a reduced version thereof (called Lf...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MANZANARES MIR PALOMA, VALLES ALVENTOSA SALVADOR, ENRIQUE LOPEZ MARIA, CENTENO GUIL JOSE MARIA, SALOM SALVANERO JOAN BTA, MARCOS LOPEZ JOSE FCO
Format:	Patent
Sprache:	spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE FOODS OR FOODSTUFFS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROTEIN COMPOSITIONS FOR FOODSTUFFS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE WORKING-UP PROTEINS FOR FOODSTUFFS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention consists in the use of bioactive products derived from dairy proteins - lactoferrin - and the hydrolyzate of lactoferrin that contains said products. This involves a peptide with fifteen amino acid residues (called LfcinB 17-31), and another that is a reduced version thereof (called LfcinB20-25), which are derived from bovine lactoferrin, as effective inhibitors of the angiotensin converting enzyme (ACE). The peptides that are the subject of the patent may be obtained chemically, enzymatically or biotechnologically and give rise to peptides with in vitro and/or ex vivo angiotensin converting enzyme inhibitory activity measured as the reduction in the contraction of rabbit carotid arteries induced by exposure to angiotensin 1. These nutraceutical products, possibly in the form of bioactive peptides, are useful both in the food industry and in the pharmaceutical industry.